Cytovance Biologics Announces Ping Zhang as Chief Executive Officer
OKLAHOMA CITY, Jan. 16, 2023 (GLOBE NEWSWIRE) -- Cytovance® Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of...
DNA
CLINUVEL Trial Results Show Drug Reduces DNA Damage
Results in “children of the moon” disorder have implications for populations at highest risk of skin cancerMELBOURNE, Australia, Jan. 16,...
IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses
Non-dilutive funding strengthens balance sheet and extends current operating runway into 2025The sale of an additional $1.8 million of unused New...
POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial
Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidanceINDIANAPOLIS, Jan. 12, 2023 (GLOBE NEWSWIRE)...
DiaCarta Receives U.S. FDA Emergency Use Authorization for its Monkeypox Test Kit
PLEASANTON, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that the U.S....
Zynerba Pharmaceuticals Announces Publication in the Journal of Neurodevelopmental Disorders Describing the Role of the Endocannabinoid System and Cannabidiol Therapy in Fragile X Syndrome
Comprehensive data review suggests a central role for the endocannabinoid system (ECS) in neuronal development, cognitive function and in the...
PharmaTher Holdings Provides Update for KETARX™ (Racemic Ketamine) Development Programs and Expected Milestones for 2023
Company aims to commercialize wholly-owned KETARX™ (racemic ketamine) for mental health, neurological and pain disorders Company aims to seek FDA...
CRISPR Therapeutics to Participate in B. Riley Securities’ 3rd Annual Oncology Conference
ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on...
Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors
DOYLESTOWN, Pa., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing novel synthetic...
Genetic Technologies Provides Business Update
MELBOURNE, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE,”Company”, “GTG”), a global leader in guideline-driven genomics-based...
Floré and DSM Partner to Revolutionize Probiotics Sector
MassChallenge Switzerland’s Sustainable Food Solutions Challenge facilitated the strategic pairing to help improve global gut health and wellnessSAN DIEGO and...
Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results
-- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M,...
Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in platform approaches to discover inhibitors of challenging...
North Louisiana Forensic Science Center to host Cannabix Marijuana Breathalyzer Technology
Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety Cannabix Technologies...
IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
LAWRENCEVILLE, NJ and PHILADELPHIA, PA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company,...
DiaCarta Announces Successful Completion of Oncuria® Validation Study with Nonagen Bioscience
DiaCarta Starts to Receive Samples for Oncuria® Bladder Cancer Test at its CLIA Lab PLEASANTON, Calif. and LOS ANGELES, Jan....
IGC Receives No Objection Letter from Health Canada
POTOMAC, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or...
New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan....
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr....
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea
Approval represents third FDA clearance for Vivos’ oral appliances and first clearance specifically recognizing Vivos’ proprietary core technologyLITTLETON, Colo., Jan. 04,...